These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38897068)
1. To give or not to give? Pandemic vaccine donation policy. Holleran A; Martonosi SE; Veatch M Public Health; 2024 Aug; 233():164-169. PubMed ID: 38897068 [TBL] [Abstract][Full Text] [Related]
2. Return to normal pre-COVID-19 life is delayed by inequitable vaccine allocation and SARS-CoV-2 variants. Liu F; Zhao Z; Ma C; Nie X; Wu A; Li X Epidemiol Infect; 2022 Jan; 150():e46. PubMed ID: 35067231 [TBL] [Abstract][Full Text] [Related]
3. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia. McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236 [TBL] [Abstract][Full Text] [Related]
4. National interest may require distributing COVID-19 vaccines to other countries. Rotesi T; Pin P; Cucciniello M; Malik AA; Paintsil EE; Bokemper SE; Willebrand K; Huber GA; Melegaro A; Omer SB Sci Rep; 2021 Sep; 11(1):18253. PubMed ID: 34521916 [TBL] [Abstract][Full Text] [Related]
5. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. MacIntyre CR; Costantino V; Trent M Vaccine; 2022 Apr; 40(17):2506-2513. PubMed ID: 33958223 [TBL] [Abstract][Full Text] [Related]
6. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts. Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200 [TBL] [Abstract][Full Text] [Related]
7. The COVID-19 Vaccination and Vaccine Inequity Worldwide: An Empirical Study Based on Global Data. Ning C; Wang H; Wu J; Chen Q; Pei H; Gao H Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564661 [TBL] [Abstract][Full Text] [Related]
8. The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants. Yadegari I; Omidi M; Smith SR Sci Rep; 2021 Nov; 11(1):22970. PubMed ID: 34836984 [TBL] [Abstract][Full Text] [Related]
9. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study. Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829 [TBL] [Abstract][Full Text] [Related]
10. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
11. Optimal vaccine allocation for COVID-19 in the Netherlands: A data-driven prioritization. Miura F; Leung KY; Klinkenberg D; Ainslie KEC; Wallinga J PLoS Comput Biol; 2021 Dec; 17(12):e1009697. PubMed ID: 34898617 [TBL] [Abstract][Full Text] [Related]
12. Herd immunity: challenges and the way forward in Korea. Oh J; Kim S; Ryu B; Shin M; Kim BI Epidemiol Health; 2021; 43():e2021054. PubMed ID: 34412446 [TBL] [Abstract][Full Text] [Related]
13. COVAX, vaccine donations and the politics of global vaccine inequity. de Bengy Puyvallée A; Storeng KT Global Health; 2022 Mar; 18(1):26. PubMed ID: 35248116 [TBL] [Abstract][Full Text] [Related]
14. A flexible age-dependent, spatially-stratified predictive model for the spread of COVID-19, accounting for multiple viral variants and vaccines. Schneider KA; Tsoungui Obama HCJ; Adil Mahmoud Yousif N PLoS One; 2023; 18(1):e0277505. PubMed ID: 36662784 [TBL] [Abstract][Full Text] [Related]
15. Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19. Taboe HB; Asare-Baah M; Iboi EA; Ngonghala CN Math Biosci; 2023 Jun; 360():108981. PubMed ID: 36803672 [TBL] [Abstract][Full Text] [Related]
16. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity. Kouamou V; Matarise R; Santos ED; Elose N; Manasa J Pan Afr Med J; 2021; 39():255. PubMed ID: 34707756 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type. Totolian AA; Smirnov VS; Krasnov AA; Ramsay ES; Dedkov VG; Popova AY Viruses; 2023 Oct; 15(11):. PubMed ID: 38005859 [No Abstract] [Full Text] [Related]
19. Mutations make pandemics worse or better: modeling SARS-CoV-2 variants and imperfect vaccination. Bugalia S; Tripathi JP; Wang H J Math Biol; 2024 Mar; 88(4):45. PubMed ID: 38507066 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]